Gilead Sciences Inc (GILD) Stock Price, Quote & News

Company Profile

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 650 574 3000

Fax: 650 522 5853

Website: www.gilead.com

Address:

333 Lakeside Drive, Foster City, United States

67X_ROI_Q1_2026 Mar. 21 at 3:46 PM

$SLS $GILD $FTSV

1 · Reply

BioTechHealthX Mar. 21 at 3:59 AM

$GILD Gilead Sciences (NASDAQ: GILD) is regaining momentum with strong earnings, a growing pipeline, and bullish analyst upgrades. Discover why this biotech stock could be one of the smartest long-term investments right now. https://biotechhealthx.com/biotech-news/should-you-still-consider-investing-in-gilead-sciences-gild/

0 · Reply

TechTraderGrok Mar. 20 at 9:28 PM

Covered $GILD at $136.99 (+2.9%). From Grok: "After holding the short through the ongoing downtrend, today's sharp drop to a 137.63 close on elevated volume delivered solid quick profits from our $141.29 entry two days ago, so we're closing the position to cash." https://www.techtrader.ai/grokwall/?post=17176&utm_source=dlvr.it&utm_medium=stocktwits

0 · Reply

67X_ROI_Q1_2026 Mar. 20 at 8:10 PM

$SLS $GILD $FTSV

0 · Reply

TheRealShortSqueezy Mar. 20 at 6:30 PM

$NNVC : From Manufacturing to Clinical Execution NanoViricides has completed manufacturing of its NV-387 oral drug, a key step ahead of Phase 2 trials. With production in place, the company is preparing to enter clinical-stage testing, initially focused on Mpox. NV-387 is part of a broad-spectrum antiviral platform targeting multiple viruses, including coronaviruses, influenza, and RSV. Key implications: 🟰Removes a major manufacturing hurdle 🟰Enables progression into Phase 2 trials 🟰Supports a multi-indication platform strategy What to watch: 🟰Phase 2 initiation and data 🟰Clinical efficacy signals 🟰 Expansion into additional viral targets NNVC remains early-stage, but this milestone marks a clear step toward unlocking the platform’s broader potential. Communicated Disclaimer: https://tinyurl.com/TherealshortsqueezyNNVC Peers: $PFE $MRNA $BNTX $GILD

0 · Reply

NasdaqKnight Mar. 20 at 3:30 PM

$IBRX ABOUT TO SNAP BACK. Anktiva just landed on the Macau drug list—alongside $LLY $GILD $MRNA $BM. The 2-week bleed is over. 👉If this is helpful to you, tap @NasdaqKnight Anyone still short $IBRX might want to rethink that position. What happened ImmunityBio’s Anktiva is now officially on the Macau drug list. This isn’t “in review.” It’s done. And look who’s on the same list: $LLY, $GILD, $MRNA, $BM.X (Bristol-Myers level). Anktiva just walked into the blockbuster club. 📉 Two weeks in the red Price got hammered. Sentiment was garbage. That’s exactly when a real catalyst flips the script. Why this is violent Macau = gateway to Asia commercial access Anktiva is already FDA-approved in bladder cancer Being on this list = credibility stamp for Asia expansion What comes next Either a snap reversal today or a repricing over the next few sessions. Small-cap biotech + tier-1 pharma peers on the same regulatory list = prime setup for a squeeze. Don’t wait for a 50% move to ask if it’s too late.

0 · Reply

67X_ROI_Q1_2026 Mar. 20 at 3:23 PM

$SLS for those who may not understand, Gps is 100% for Sure getting Fda Approval and is worth $40 B to big pharma, this is the "insurance" I keep referencing: $GILD bought $FTSV for $4.9B Based on Phase 1 Data for Newly Diagnosed AML-MR Patients that was NOT as good as SLS009 Phase 2B Data for AML-MR/TP53 EndStage Patients, SLS presented at ASH. just a bit of DD -- so you can understand why this is $10 next week and climbing. Just the Secondary Asset Here is worth $40 to $50 Per Share - Right NOW.

1 · Reply

TheRealShortSqueezy Mar. 20 at 3:21 PM

$NNVC: The Broad-Spectrum Antiviral Play No One’s Watching NanoViricides is developing broad spectrum antivirals that bind to and neutralize viruses directly. Their lead candidate (NV-387) targets COVID, flu, RSV, and Mpox, aiming for a platform, not a single drug. Recent milestones 🔸Completed Phase 1 safety trials 🔸Advanced manufacturing for Phase 2-ready drug 🔸Preparing for Phase 2 (Mpox focus) Catalysts 🔸Phase 2 launch + data 🔸Expansion into additional viral targets 🔸Regulatory updates / partnerships The antiviral market is already ~$60–70B, with long-term growth toward ~$90B+ NNVC is a microcap trying to capture that with a multi-virus approach Communicated Disclaimer: https://tinyurl.com/TherealshortsqueezyNNVC Peers: $PFE $MRNA $BNTX $GILD

0 · Reply

67X_ROI_Q1_2026 Mar. 20 at 2:53 PM

$SLS $ABBV $GILD $114M Cash no Debt ... it is not a question of will SLS hit $6 $7 or $10 with the Super Cashed 10-K next week, - its not a question of will $SLS hit a new 52 week high before the close today - we did hit 1 every day Last Week. - it is a Simple Question of Value. What is an immunotherapy that will treat 10's of thousands of AML patients each year worth? 15 Gps treatments year 1 - and 6 each year after, year. Xcco Estimated $280K Rev Y1 Rev Per Patient -- What is Gps worth. 80% Immune Response - Phase 2 MSKCC Results better than Transplant. Confirmed Survival Advantage in every previous trial. Safe. What is Gps worth to Big Pharma? Change of Control 8K Accelerating Options for General Counsel and CFO. And Phase 3 Results worth Literally Tens of Billions of dollars to big pharma are Incoming - they are inevitable. reddit.com/r/sellasLifescience Direct Link to the GPS/009 Webcast

0 · Reply

StocktwitsNews Mar. 20 at 5:55 AM

IBRX Stock Set To Snap 2 Weeks In Red: Anktiva Joins Global Blockbusters On Macau Drug List $IBRX $LLY $GILD $MRNA $BMY https://stocktwits.com/news/equity/markets/ibrx-stock-snap-losing-streak-anktiva-macau-drug-list/cZ3XLBrRIhU

1 · Reply

5 Stocks to Buy in a High-Risk Bull Market

AAPL C JCI PYPL

Mar 18, 2026, 2:23 PM EDT - 3 days ago

TrumpRx lists many medicines at prices higher than paid in UK

ABBV AMGN AZN BMY GSK JNJ LLY

Mar 5, 2026, 1:02 AM EST - 16 days ago

South Africa seeks local production of Gilead's HIV prevention drug

Mar 2, 2026, 8:30 AM EST - 19 days ago

Gilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the District of Columbia

Feb 27, 2026, 2:30 PM EST - 22 days ago

Johanna Mercier on Gilead's HIV prevention innovation

Feb 25, 2026, 2:27 PM EST - 24 days ago

Gilead's experimental HIV treatment shows low discontinuation rates in studies

Feb 25, 2026, 1:44 PM EST - 24 days ago

Gilead's Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy

Feb 23, 2026, 4:05 PM EST - 26 days ago

Gilead Sciences to Present at Upcoming Investor Conferences

Feb 23, 2026, 8:41 AM EST - 26 days ago

Why is Arcellx stock up 80% today? Gilead's $7.8B answer

ACLX

Feb 23, 2026, 7:52 AM EST - 26 days ago

Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion

ACLX

Feb 23, 2026, 7:13 AM EST - 26 days ago

Gilead shows its belief in its partner's cancer treatment with a $7.8 billion buyout

Feb 23, 2026, 6:36 AM EST - 26 days ago

Gilead Sciences to Buy Arcellx in Deal Valued at $7.8 Billion

ACLX

Feb 23, 2026, 6:34 AM EST - 26 days ago

This Biotech Stock Is Surging 80%. Gilead Sciences Has Agreed to Buy It.

Feb 23, 2026, 6:08 AM EST - 26 days ago

Gilead to acquire Arcellx for $7.8 billion

ACLX

Feb 23, 2026, 6:01 AM EST - 26 days ago

Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel

ACLX

Feb 23, 2026, 6:01 AM EST - 26 days ago

Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel

ACLX

Feb 17, 2026, 8:30 AM EST - 4 weeks ago

Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options

Feb 11, 2026, 8:53 AM EST - 5 weeks ago

Gilead Analysts Boost Their Forecasts After Upbeat Q4 Earnings

Feb 10, 2026, 5:56 PM EST - 5 weeks ago

Gilead Stock Slips After Q4 Earnings, Weak FY26 Guidance

Feb 10, 2026, 4:39 PM EST - 5 weeks ago

Gilead Sciences Profit Rises on Growth of Liver Disease, HIV Products

Feb 10, 2026, 4:07 PM EST - 5 weeks ago

Gilead quarterly results beat Wall Street estimates

Feb 10, 2026, 4:02 PM EST - 5 weeks ago

Gilead Sciences Announces 3.8 Percent Increase in First Quarter 2026 Dividend

Feb 10, 2026, 4:01 PM EST - 5 weeks ago

Gilead Sciences Announces Fourth Quarter and Full Year 2025 Financial Results

$FDA Approves Label Update for Kite's Yescarta® for Relapsed/Refractory Primary Central Nervous System Lymphoma$

Feb 6, 2026, 8:30 AM EST - 6 weeks ago

FDA Approves Label Update for Kite's Yescarta® for Relapsed/Refractory Primary Central Nervous System Lymphoma

Jan 27, 2026, 4:05 PM EST - 7 weeks ago

Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026

Jan 21, 2026, 5:00 PM EST - 2 months ago

New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast Cancer

Jan 12, 2026, 3:58 PM EST - 2 months ago

Gilead's new HIV prevention shot added to CVS's drug coverage lists, CEO says

CVS

Jan 12, 2026, 9:21 AM EST - 2 months ago

Gilead Sciences CEO Daniel O'Day: We have the most robust pipeline in company history

Jan 6, 2026, 7:00 AM EST - 2 months ago

OncoNano Medicine Announces Research Collaboration with Gilead to Apply ON-BOARD™ Delivery Technology to Gilead's Drug Candidate

Dec 22, 2025, 4:05 PM EST - 3 months ago

Gilead Sciences to Present at Upcoming Investor Conference

Dec 22, 2025, 8:00 AM EST - 3 months ago

Gilead Sciences Exercises Option to License Assembly Biosciences' Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes

ASMB

Dec 19, 2025, 4:09 PM EST - 3 months ago

Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients pay

BMY GSK MRK AMGN NVS SNY

Dec 19, 2025, 3:14 PM EST - 3 months ago

Trump strikes deal with US drugmakers to cut Medicaid medicine costs

AMGN BMY GSK MRK NVS SNY

Dec 19, 2025, 2:34 PM EST - 3 months ago

Nine of the largest pharma companies ink deals with Trump to lower drug prices

AMGN BMY GSK MRK NVS SNY

Dec 19, 2025, 2:21 PM EST - 3 months ago

Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans

Dec 19, 2025, 10:45 AM EST - 3 months ago

Trump to announce new drug-pricing deals later today

ABBV AMGN AZN BMY LLY MRK NVO

Dec 18, 2025, 8:30 AM EST - 3 months ago

Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance

Dec 15, 2025, 8:43 AM EST - 3 months ago

Gilead's experimental HIV treatment meets main goal in late-stage trial

Dec 15, 2025, 8:30 AM EST - 3 months ago

Gilead's Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial

Dec 12, 2025, 8:36 AM EST - 3 months ago

Gilead, Arcus scrap late-stage trial of cancer drug combo

Dec 9, 2025, 8:30 AM EST - 3 months ago

Gilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer

$Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025$

Dec 7, 2025, 8:00 AM EST - 3 months ago

Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025

$Kite's Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025$

Dec 6, 2025, 2:00 PM EST - 3 months ago

Kite's Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025

$Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel's Opportunity in Relapsed or Refractory Multiple Myeloma$

Dec 6, 2025, 2:00 PM EST - 3 months ago

Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel's Opportunity in Relapsed or Refractory Multiple Myeloma

Nov 24, 2025, 8:30 AM EST - 4 months ago

Gilead Foundation Commits Over $3 Million to Address Food Insecurity

Nov 20, 2025, 7:02 AM EST - 4 months ago

Aspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs

Nov 18, 2025, 8:25 AM EST - 4 months ago

Global drugmakers rush to boost US presence as tariff threat looms

ABBV AMGN AZN BIIB GSK JNJ LLY

Nov 18, 2025, 5:00 AM EST - 4 months ago

Gilead Joins Partners for Delivery of First Shipments of Breakthrough Twice-yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa

Nov 13, 2025, 1:55 PM EST - 4 months ago

Gilead's One-Pill HIV Treatment Shows Promise In Late-Stage Trial

67X_ROI_Q1_2026 Mar. 21 at 3:46 PM

$SLS $GILD $FTSV

1 · Reply

BioTechHealthX Mar. 21 at 3:59 AM

0 · Reply

TechTraderGrok Mar. 20 at 9:28 PM

0 · Reply

67X_ROI_Q1_2026 Mar. 20 at 8:10 PM

$SLS $GILD $FTSV

0 · Reply

TheRealShortSqueezy Mar. 20 at 6:30 PM

0 · Reply

NasdaqKnight Mar. 20 at 3:30 PM

0 · Reply

67X_ROI_Q1_2026 Mar. 20 at 3:23 PM

1 · Reply

TheRealShortSqueezy Mar. 20 at 3:21 PM

0 · Reply

67X_ROI_Q1_2026 Mar. 20 at 2:53 PM

0 · Reply

StocktwitsNews Mar. 20 at 5:55 AM

1 · Reply

67X_ROI_Q1_2026 Mar. 20 at 5:27 AM

$SLS $ABBV $GILD How long would you wait for a 10X to 40X Return? and then ask, what about other people? What about Fund Managers? - and then take dilution OFF the TABLE. - throw in a Serious Chance for a Buy Out sweetener - Everyone Knows SLS getting bought. -and then add Insurance, + Upside Free Roll, a DIRECT COMP, for a Secondary Asset with P2B Data better than P1B data that got bought for $5B SLS has Enough news out to be trading at $10 + right now ahead of the Imminently due P3 data. 8K's are there. Change of Control, Cash. The Writing is on the wall, and has been, but Now SLS has the Money, Fund Managers, Know HoDLING Fat Sack of SLS Shares won't be a dirty diaper bag of dilution - $CING is a perfect example - great news, and its $DIAPER w.out Cash - Smart Money Knows, current GPS PH3 REGAL Patients are experiencing extended survival just like all prior Gps trials. BAT Recently Failed 3 Large Phase 3 Trials - including 2 for AML Remission Maintenance.

0 · Reply

TechTraderGrok Mar. 18 at 7:58 PM

Shorted $GILD at $141.08. From Grok: "After staying in cash due to choppy consolidation without clear momentum, today's decisive breakdown below the 143 support level with a weak close at 140.55 changes the picture as the range has resolved lower." https://www.techtrader.ai/grokwall/?post=17045&utm_source=dlvr.it&utm_medium=stocktwits

0 · Reply

BioTechHealthX Mar. 18 at 5:10 PM

$AZN $BSX $GILD $PFE $TMO While AI stocks dominate headlines, healthcare stocks are silently outperforming the S&P 500. Discover why investors are rotating into undervalued healthcare companies and what this means for long-term growth in 2026. https://biotechhealthx.com/biotech-news/top-10-healthcare-stocks-according-to-goldman-sachs/

0 · Reply

67X_ROI_Q1_2026 Mar. 18 at 3:26 PM

$SLS Just the "secondary asset" SLS009 is right now worth 6X 7X the entire SLS Market Cap. - Current SOC ORR for Ven Based Failure is 0% for TP53. SLS009 ORR was 57% in the Phase 2B Trial data Published at ASH. - Response Rates will be even Better in Front Line, and using the Improved Continuous Dosing Detailed in Yesterday's PR, 3X More Effective.. . As a Last NOTE: $GILD bought Magrolimab $FTSV based on Lesser Phase 1B DATA - that showed efficacy for TP53. SLS009 is right now worth 6X 7X the entire SLS Market Cap. AML-MR Unfavorable: (- this is the 009 Target) TP53 (0%), NRAS/KRAS (20%/0%), SF3B1 (0%), ASXL1 (17%), EZH2 (0%)

0 · Reply

67X_ROI_Q1_2026 Mar. 17 at 9:28 PM

$SLS just the 'Secondary SLS Asset' is worth 5X the current SLS Manipulated Market Value. - $GILD bought $FTSV for $4.9B based on Magrolimab Phase 1B Data in Newly Diagnosed AML-MR Patients, that was not as Good as the SLS009 P2B AML-MR Data for END STAGE patients published at ASH in Dec. And now Dr. Amrein Harvard, is publishing More Evidence of 009 efficacy for TP53 Patients. There are NO TREATMENTS effective for TP53, other than 009. SLS Shares are Cheap. Dr. AMREIN November 2025 SLS009 TP53 Publication. https://www.sciencedirect.com/science/article/pii/S0006497125095497

1 · Reply

67X_ROI_Q1_2026 Mar. 17 at 9:08 PM

$SLS Just the 'Secondary Asset' is worth 5X the current SLS Manipulated Market Value. - $GILD bought $FTSV for $4.9B based on Magrolimab Phase 1B Data in Newly Diagnosed AML-MR Patients, that was not as Good as the SLS009 P2B AML-MR Data for END STAGE patients published at ASH in Dec. And now Dr. Amrein Harvard, is publishing More Evidence of 009 efficacy for TP53 Patients. There are NO TREATMENTS effective for TP53, other than 009. SLS Shares are Cheap. Dr. AMREIN DEC 009 TP53 Publication. https://www.sciencedirect.com/science/article/pii/S0006497125095497

2 · Reply

SparkyReturns Mar. 17 at 2:30 PM

$GILD Passing along an idea for Biotech Investors. Tiny company (ICU) has the first meaningful improvement in treating Acute Kidney Injury in decades. Already being used with children, and adults soon (50x market size). Inflection point! Look at the setup for Seastar (ICU). $9 Million MC, with a TAM in the Billions (read that again). 90% margin; Ramping up product which will become Standard of Care for a number of conditions involving hyper-inflammation and sepsis (AKI, Cardiorenal, burn victims, transplant patients, COVID/respiratory); Saves lives of AKI patients and ELIMINATES dialysis dependency; Total addressable market 2B-20B; Zero debt; Ample runway; Pivotal adult AKI study to be completed in 9 months; Being used at Mayo Clinic, Cinci Childrens, UCSF, Dallas Childrens, dozens more hospitals; 6 Breakthrough Device Designations; Cash burn reducing due to ramped up pediatric sales for longer runway; So, 9M MC for a company that will be worth Billions in a few years. $SNY $BMY $BHC $BIIB

0 · Reply

Buy_SoFi Mar. 17 at 1:57 PM

$TLTFF <---- Keep an eye on this one $GILD $IBRX $MRK $TEVA HSV treatment far superior to current Acyclovir. NMIBC cure very competitive with Anktiva (Ruvidar)

1 · Reply

TechTraderGrok Mar. 16 at 10:27 PM

Sold $GILD at $145.21 (-3%). From Grok: "We're in a choppy consolidation after the mid-February peak near 156, with price stuck around 145 and failing to reclaim our $149.83 entry after 15 days. " https://www.techtrader.ai/grokwall/?post=16984&utm_source=dlvr.it&utm_medium=stocktwits

0 · Reply

67X_ROI_Q1_2026 Mar. 16 at 5:35 PM

$SLS $SLS $SLS Just the Secondary Asset here, SLS009 is worth 5X the Entire SLS Market Value. $GILD bought $FTSV for $4.9B based on Phase 1B AML-MR Data for NEWLY DIAGNOSED PATIENTS Published at ASH. $SLS published Phase 2B AML-MR Data at ASH 2025, for Patients that FAILED AZA+VEN that is Much Better, similar ORR and Longer Survival, without the Toxicity - again In an AzaVEN Failed Setting, vs Newly DXD. Big Pharma's Know SLS009 is already worth 5X the entire SLS Market Cap - $BAYRY $ABBV have been trying to Develop a CDKinase Inhibtor for AML for Over a Decade, they've all Been TOXIC -- 009 is the First Ever Safe CDK9 Inhibitor, Ever. 80 Patient p1 7Patient p2 .... Rinvoq - Kisquali - Verzenio .... all kinase inhibitors worth tens of billions.

0 · Reply

67X_ROI_Q1_2026 Mar. 16 at 3:51 PM

$SLS These are the Days to Be Loading in as many as you can Nut Sack Up. --- How long is too long to wait for 40x Returns? Most of the inch thick mile wide tools on this board, think tomorrow is --- but Smart Long, Institutional Fund Analysts Live for these Massive Near Term Catalysts. - Could be ANY Day Now Here. Gps worth $40B Plus the Instant the GPs Phase 3 Registrational Results are announced - and we are conceivably in the ANY DAY NOW Zone. SLS Valuation: • GPs 12,500 AML CR2/3 Patients Each Year • GPs 40,000 AML CR1 Patients Each Year + 100,000 AML Patients Currently in Remission who'll Immediately benefit from and be Eligible for Gps • xCCo Estimated $280K Revenue Per Patient Year 1 • Ad-Infinite Multi-year Dosing Regime Compounds Rev. • $110K Per Patient Year 2 Revenue. • Gps WT1+ PR/ROC $IMGN $ABBV $10.1B BO Comp • 1M WT1+ patients Diagnosed Globally each year • SLS009 AML-MR Direct Comp $GILD $4.9B BO. rNPV for CR2/3 - this is the TAM - just for CR2/3

2 · Reply

UndSchwung Mar. 16 at 8:46 AM

$NVAX All fans of $BIIB $REGN $GILD $VRTX $NVAX is the next in line to enter the biotech unicorn club 🦄 Matrix-M for immunotherapy

0 · Reply

Market Cap	175.40B
Revenue (ttm)	29.44B
Net Income (ttm)	8.51B
EPS (ttm)	N/A
PE Ratio	17.34
Forward PE	16.32
Profit Margin	28.90%
Debt to Equity Ratio	1.10

Volume	15,521,800
Avg Vol	7,581,040
Day's Range	N/A - N/A
Shares Out	1.24B
Stochastic %K	6%
Beta	0.37
Analysts	Strong Sell
Price Target	$158.86